Drug intelligence / Profile preview

bacteroides xylanisolvens ay11-1

Development stage: Preclinical
Lead developer: Ocean University of China
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bacteroides xylanisolvens AY11-1 is a strain of the gut bacterium Bacteroides xylanisolvens. It is notable for its ability to efficiently consume polyguluronate (PG), a component of dietary fiber, and produce short-chain fatty acids (SCFAs), which are beneficial metabolites in the human gut[1]. There is emerging interest in this and related strains for their potential use as live biotherapeutic products, particularly in modulating gut microbiota and treating conditions such as inflammatory bowel disease (IBD), as indicated by recent research and patent applications from academic institutions in China[CN114806962B]. However, it is not currently marketed as a pharmaceutical drug or dietary supplement.

Beyond the preview

Go deeper on bacteroides xylanisolvens ay11-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacteroides xylanisolvens ay11-1.

Explore the full profile